JP2012507271A5 - - Google Patents

Download PDF

Info

Publication number
JP2012507271A5
JP2012507271A5 JP2011533752A JP2011533752A JP2012507271A5 JP 2012507271 A5 JP2012507271 A5 JP 2012507271A5 JP 2011533752 A JP2011533752 A JP 2011533752A JP 2011533752 A JP2011533752 A JP 2011533752A JP 2012507271 A5 JP2012507271 A5 JP 2012507271A5
Authority
JP
Japan
Prior art keywords
amino acid
acid residue
group
residue selected
binding protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011533752A
Other languages
English (en)
Japanese (ja)
Other versions
JP5954990B2 (ja
JP2012507271A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2009/064483 external-priority patent/WO2010060748A1/en
Publication of JP2012507271A publication Critical patent/JP2012507271A/ja
Publication of JP2012507271A5 publication Critical patent/JP2012507271A5/ja
Application granted granted Critical
Publication of JP5954990B2 publication Critical patent/JP5954990B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011533752A 2008-11-03 2009-11-03 Vegf−aレセプター相互作用を阻害する結合タンパク質 Active JP5954990B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08168166 2008-11-03
EP08168166.0 2008-11-03
PCT/EP2009/064483 WO2010060748A1 (en) 2008-11-03 2009-11-03 Binding proteins inhibiting the vegf-a receptor interaction

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015053249A Division JP6329503B2 (ja) 2008-11-03 2015-03-17 Vegf−aレセプター相互作用を阻害する結合タンパク質

Publications (3)

Publication Number Publication Date
JP2012507271A JP2012507271A (ja) 2012-03-29
JP2012507271A5 true JP2012507271A5 (Direct) 2012-11-29
JP5954990B2 JP5954990B2 (ja) 2016-07-20

Family

ID=40149742

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011533752A Active JP5954990B2 (ja) 2008-11-03 2009-11-03 Vegf−aレセプター相互作用を阻害する結合タンパク質
JP2015053249A Active JP6329503B2 (ja) 2008-11-03 2015-03-17 Vegf−aレセプター相互作用を阻害する結合タンパク質

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015053249A Active JP6329503B2 (ja) 2008-11-03 2015-03-17 Vegf−aレセプター相互作用を阻害する結合タンパク質

Country Status (15)

Country Link
US (2) US8901076B2 (Direct)
EP (2) EP3785735A1 (Direct)
JP (2) JP5954990B2 (Direct)
KR (1) KR101698362B1 (Direct)
CN (2) CN102272148A (Direct)
AU (1) AU2009319204B2 (Direct)
BR (1) BRPI0921469B1 (Direct)
CA (1) CA2742241C (Direct)
DK (1) DK2358746T3 (Direct)
ES (1) ES2836948T3 (Direct)
IL (1) IL212589A (Direct)
MX (2) MX2011004649A (Direct)
NZ (1) NZ592591A (Direct)
RU (2) RU2650765C1 (Direct)
WO (1) WO2010060748A1 (Direct)

Families Citing this family (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9829494B2 (en) 2005-12-01 2017-11-28 Adrenomed Ag Methods of treatment using ADM antibodies
CA2648284C (en) 2006-04-07 2016-08-16 The Procter & Gamble Company Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof
AU2014243418B2 (en) * 2010-04-30 2016-09-22 Molecular Partners Ag Modified binding proteins inhibiting the VEGF-A receptor interaction
AR081361A1 (es) 2010-04-30 2012-08-29 Molecular Partners Ag Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a
EP3514169B1 (en) 2010-11-26 2024-03-06 Molecular Partners AG Designed repeat proteins binding to serum albumin
EA201391607A1 (ru) 2011-04-29 2014-04-30 Янссен Байотек, Инк. Связывающие il4/il13 белки с повторами и их применение
WO2012172054A1 (en) 2011-06-16 2012-12-20 Scil Proteins Gmbh Modified multimeric ubiquitin proteins binding vegf-a
CN104039351A (zh) 2011-10-13 2014-09-10 阿尔皮奥治疗学股份有限公司 用于治疗血管渗漏综合征和癌症的方法
US9402900B2 (en) 2011-11-16 2016-08-02 Adrenomed Ag Methods of modulating adrenomedullin by administering an anti-adrenomedullin (ADM) antibody
MX355482B (es) 2011-11-16 2018-04-19 Adrenomed Ag Anticuerpo anti - adrenomedulina (adm) o fragmento de anticuerpo anti - adm o un andamio no ig anti - adm para usarse en terapia.
RS64060B1 (sr) 2011-11-16 2023-04-28 Adrenomed Ag Antitelo na anti-adrenomedulin (adm) ili fragment antitela na adm ili struktura antitela na adm bez ig za sprečavanje ili smanjenje disfunkcije organa ili insuficijencije organa kod pacijenta koji ima hroničnu ili akutnu bolest ili akutno stanje
MY174877A (en) 2011-11-16 2020-05-20 Adrenomed Ag Anti-adrenomedullin (adm) antibpdy or anti-adm antibody fragment of anti-adm non-ig scaffold for prevention or reduction of organ dysfunction or organ failure in a patient having a chronic of acute disease or acute condition
PL2780371T3 (pl) 2011-11-16 2019-06-28 Adrenomed Ag Przeciwciało przeciwko adrenomedulinie (ADM) lub fragment przeciwciała przeciwko ADM lub rusztowanie nie-Ig przeciwko ADM do regulowania równowagi płynów u pacjenta z chorobą przewlekłą lub ostrą
SG11201402362VA (en) 2011-11-16 2014-06-27 Adrenomed Ag Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition
CN103308673B (zh) 2012-03-08 2017-05-31 思芬构技术有限公司 用于预测雌性对象中发生心血管事件的风险的方法
CN103308689B (zh) 2012-03-08 2017-04-12 思芬构技术有限公司 用于预测雌性对象中患上癌症的风险或诊断癌症的方法
CN103308670B (zh) 2012-03-08 2017-06-09 思芬构技术有限公司 用于预测对象患糖尿病和/或代谢综合征的风险的方法
PL2846836T3 (pl) * 2012-05-07 2020-01-31 Allergan, Inc. Sposób leczenia amd u pacjentów opornych na terapię anty- vegf
KR102288287B1 (ko) 2012-06-01 2021-08-11 노파르티스 아게 시린지
KR20150023957A (ko) * 2012-06-28 2015-03-05 몰리큘라 파트너스 아게 혈소판-유래 성장인자에 결합하는 설계된 안키린 반복 단백질
JOP20200175A1 (ar) 2012-07-03 2017-06-16 Novartis Ag حقنة
AU2012101677B4 (en) 2012-07-03 2012-12-20 Novartis Ag Device
AU2013100071C4 (en) * 2012-07-03 2013-05-02 Novartis Ag Device
JP2015528454A (ja) * 2012-08-28 2015-09-28 ノバルティス アーゲー 眼血管増殖性疾患の処置におけるvegfアンタゴニストの使用
TR201809001T4 (tr) 2012-10-02 2018-07-23 Sphingotec Gmbh Böbrek fonksiyonunu teşhis etmek veya izlemek veya böbrek fonksiyonu bozukluğunu teşhis etmek için bir usul.
EP2738180A1 (en) 2012-11-30 2014-06-04 Molecular Partners AG Binding proteins comprising at least two binding domains against HER2.
EP2943795B1 (en) 2013-01-08 2021-02-24 sphingotec GmbH Fasting levels of growth hormone as a predictive marker of cardiovascular risk
KR20150122761A (ko) * 2013-02-26 2015-11-02 로슈 글리카트 아게 T 세포 활성화 항원 결합 분자
CA2902547A1 (en) * 2013-03-14 2014-09-25 Allergan, Inc. Composition of a sustained-release delivery and method of stabilizing proteins during fabrication process
SG10201800309SA (en) 2013-03-20 2018-02-27 Sphingotec Gmbh Adrenomedullin to guide therapy of blood pressure decline
FR3004650B1 (fr) * 2013-04-22 2015-05-29 Affilogic Composition topique comprenant un variant d'une protéine sauvage à pli-OB, ainsi que son procédé de préparation
EP3004152B1 (en) 2013-05-31 2020-09-30 Molecular Partners AG Designed ankyrin repeat proteins binding to hepatocyte growth factor
US20160129080A1 (en) 2013-06-20 2016-05-12 Aaron Osborne Treatment of polypoidal chroidal vasculopathy
WO2014203182A1 (en) 2013-06-20 2014-12-24 Novartis Ag Use of a vegf antagonist in treating choroidal neovascularisation
WO2014203183A1 (en) 2013-06-20 2014-12-24 Novartis Ag Use of a vegf antagonist in treating macular edema
MX2016000384A (es) 2013-07-11 2016-04-29 Novartis Ag Uso de un antagonista de vegf en el tratamiento de trastornos coriorretinianos neovasculares y de permeabilidad en pacientes pediatricos.
BR112016000282A2 (pt) 2013-07-11 2017-12-12 Novartis Ag uso de antagonista de vegf em tratamento de retinopatia da prematuridade
MX2016000364A (es) 2013-07-12 2016-05-09 Ophthotech Corp Metodos para tratar o prevenir afecciones oftalmologicas.
CN105960247A (zh) 2013-11-05 2016-09-21 阿勒根公司 用抗vegf darpin治疗眼病的方法
EP3828202A1 (en) 2014-05-12 2021-06-02 Formycon AG Pre-filled plastic syringe containing a vegf antagonist
EP3002589A1 (en) 2014-10-01 2016-04-06 sphingotec GmbH A method for stratifying a female subject for hormone replacement therapy
IL276944B (en) * 2015-04-02 2022-07-01 Molecular Partners Ag Designed ankyrin repeat domains with binding specificity for serum albumin
RU2733471C2 (ru) 2015-04-24 2020-10-01 Сфинготек Гмбх Способ прогнозирования риска развития хронического заболевания почек
TWI799366B (zh) 2015-09-15 2023-04-21 美商建南德克公司 胱胺酸結骨架平臺
US10925927B2 (en) 2015-11-18 2021-02-23 Formycon Ag Pre-filled pharmaceutical package comprising a liquid formulation of a VEGF-antagonist
EP3377040B8 (en) 2015-11-18 2024-06-05 SiO2 Medical Products, Inc. Pharmaceutical package for ophthalmic formulations
EP3377151A1 (en) 2015-11-18 2018-09-26 Formycon AG Pre-filled plastic syringe containing a vegf antagonist
WO2017129685A1 (en) 2016-01-26 2017-08-03 Formycon Ag Liquid formulation of a vegf antagonist
US11099185B2 (en) 2016-02-29 2021-08-24 Maintect Gmbh Predictive markers useful in the treatment of wet age-related macular degeneration
EP3446125B1 (en) 2016-04-21 2024-08-28 4TEEN4 Pharmaceuticals GmbH Methods for determining dpp3 and diagnostic methods
MA45493A (fr) 2016-06-27 2019-05-01 Aicuris Anti Infective Cures Gmbh Inhibiteurs d'entrée de hcmv.
ES2948446T3 (es) 2016-07-08 2023-09-12 Sphingotec Gmbh Adrenomedulina para la valoración de la congestión en un sujeto con insuficiencia cardiaca aguda
WO2018017714A1 (en) 2016-07-20 2018-01-25 Aerpio Therapeutics, Inc. HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß)
JP6976335B2 (ja) 2016-09-22 2021-12-08 モレキュラー パートナーズ アクチェンゲゼルシャフト 組み換え結合タンパク質及びその使用
EP3309550A1 (en) 2016-10-12 2018-04-18 sphingotec GmbH Method for the detection of apolipoprotein e4
EP3339324A1 (en) 2016-12-22 2018-06-27 sphingotec GmbH Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in intervention and therapy of congestion in a patient in need thereof
AU2017375049B2 (en) 2016-12-16 2025-01-30 Adrenomed Ag Anti-Adrenomedullin (ADM) antibody or anti-ADM antibody fragment or anti-ADM non-Ig scaffold for use in intervention and therapy of congestion in a patient in need thereof
US20200237997A1 (en) 2017-05-24 2020-07-30 Formycon Ag Sterilizable pre-filled pharmaceutical packages comprising a liquid formulation of a vegf-antagonist
CA3063995A1 (en) 2017-05-24 2018-11-29 Sio2 Medical Products, Inc. Sterilizable pharmaceutical package for ophthalmic formulations
WO2018215580A1 (en) 2017-05-24 2018-11-29 Formycon Ag Method for sterilizing prefilled plastic syringes containing a vegf antagonist
US20200182885A1 (en) 2017-05-30 2020-06-11 Sphingotec Gmbh A method for diagnosing or monitoring kidney function or diagnosing kidney dysfuntion
TW201904610A (zh) 2017-06-14 2019-02-01 德商拜耳製藥公司 用於治療新生血管型青光眼之非抗體vegf拮抗劑
WO2019020777A1 (en) 2017-07-26 2019-01-31 Formycon Ag LIQUID FORMULATION OF A VEGF ANTAGONIST
CN111225976A (zh) * 2017-08-18 2020-06-02 剑桥企业有限公司 模块化结合蛋白
CA3076691A1 (en) 2017-09-25 2019-03-28 Adrenomed Ag Anti-adrenomedullin (adm) binder for use in therapy or prevention of symptoms of illness
AU2018350861A1 (en) 2017-10-18 2020-04-09 Adrenomed Ag Therapy monitoring under treatment with an anti-adrenomedullin (ADM) binder
SG11202002391PA (en) 2017-10-24 2020-04-29 Sphingotec Gmbh Selenoprotein p for prediction of a first cardiovascular event
CA3080251A1 (en) 2017-10-25 2019-05-02 4TEEN4 Pharmaceuticals GmbH Dpp3 binder directed to and binding to specific dpp3-epitopes and its use in the prevention or treatment of diseases / acute conditions that are associated with oxidative stress
CN119770645A (zh) 2018-02-08 2025-04-08 斯弗因高泰克有限公司 用于诊断和/或预测痴呆症的肾上腺髓质素和抗肾上腺髓质素结合物在治疗或预防痴呆症中的应用
EP3569614A1 (en) 2018-05-18 2019-11-20 Julius-Maximilians-Universität Würzburg Compounds and methods for the immobilization of myostatin-inhibitors on the extracellular matrix by transglutaminase
EP3586865A1 (en) 2018-06-21 2020-01-01 Charité - Universitätsmedizin Berlin Complement anaphylatoxin binders and their use in treatment of a subject having an ocular wound and/or fibrosis
JP7695187B2 (ja) 2018-09-24 2025-06-18 アイポイント ファーマシューティカルズ, インコーポレイテッド HPTP-β(VE-PTP)およびVEGFを標的にする多特異性抗体
BR112021010069A2 (pt) 2018-12-20 2021-11-23 Sphingotec Gmbh Selenoproteína p em insuficiência cardíaca
CN113557031A (zh) 2018-12-21 2021-10-26 4Teen4制药有限公司 使用血管紧张肽受体激动剂和/或其前体的治疗的疗法指导和/或疗法监测
BR112021024236A2 (pt) 2019-06-04 2022-04-26 Molecular Partners Ag Proteínas multiespecíficas
JP7612666B2 (ja) 2019-08-15 2025-01-14 シュピーンゴテック ゲゼルシャフト ミット ベシュレンクテル ハフツング 小児患者における腎機能を診断若しくはモニタリングする、又は腎機能障害を診断する方法
CA3148275A1 (en) 2019-08-30 2021-03-04 4TEEN4 Pharmaceuticals GmbH Therapy guidance and/or therapy monitoring for treatment of shock
WO2021116469A2 (en) 2019-12-11 2021-06-17 Molecular Partners Ag Recombinant peptide-mhc complex binding proteins and their generation and use
EP3871689A1 (en) 2020-02-26 2021-09-01 sphingotec GmbH Anti-adm-antibodies binding to the free n-terminus for accelerated transition of adm-gly to bio-adm in patients with adm-gly/ bio-adm ratio above a threshold and combination with vitamin c
CA3172349A1 (en) 2020-02-27 2021-09-02 4TEEN4 Pharmaceuticals GmbH Dpp3 for therapy guidance, monitoring and stratification of nt-adm antibodies in patients with shock
EP4110812A2 (en) 2020-02-27 2023-01-04 AdrenoMed AG Anti-adrenomedullin (adm) binder for use in therapy of patients in shock
EP4110811A1 (en) 2020-02-27 2023-01-04 AdrenoMed AG Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock
CN115769076A (zh) 2020-03-16 2023-03-07 4Teen4制药有限公司 感染冠状病毒的患者中的dpp3
EP3922993A1 (en) 2020-06-12 2021-12-15 4TEEN4 Pharmaceuticals GmbH Dpp3 in patients infected with coronavirus
JP2023518380A (ja) 2020-03-16 2023-05-01 アドレノメト アクチェンゲゼルシャフト コロナウイルスに感染した患者におけるプロアドレノメデュリンまたはそのフラグメント、およびアドレノメデュリンに対する結合剤による治療
TW202208404A (zh) 2020-05-06 2022-03-01 瑞士商分子組合公司 新穎錨蛋白重複結合蛋白質及其用途
US12331090B2 (en) 2020-05-14 2025-06-17 Molecular Partners Ag Multispecific proteins
EP4023218A1 (en) 2020-12-02 2022-07-06 S-Form Pharma Combination therapy for patients having acute and/or persistent dyspnea
JP2023554351A (ja) 2020-12-16 2023-12-27 モレキュラー パートナーズ アクチェンゲゼルシャフト 新規の徐放性プロドラッグ
EP4304729A1 (en) 2021-03-09 2024-01-17 Molecular Partners AG Novel darpin based cd123 engagers
US11834504B2 (en) 2021-03-09 2023-12-05 Molecular Partners Ag DARPin based multi-specific t-cell engagers
EP4304730A1 (en) 2021-03-09 2024-01-17 Molecular Partners AG Novel darpin based cd33 engagers
JP2024509890A (ja) 2021-03-09 2024-03-05 モレキュラー パートナーズ アクチェンゲゼルシャフト プロテアーゼ切断可能なプロドラッグ
US12472148B2 (en) 2021-04-26 2025-11-18 Celanese Eva Performance Polymers Llc Implantable device for sustained release of a macromolecular drug compound
EP4356139A1 (en) 2021-06-18 2024-04-24 sphingotec GmbH A method for predicting sepsis and septic shock
EP4363859A1 (en) 2021-06-29 2024-05-08 berYsol GmbH Composite biomarker for the identification of selenium deficiency in a bodily fluid
EP4145456A1 (en) 2021-09-06 2023-03-08 Bayer AG Prediction of a change related to a macular fluid
KR20240122764A (ko) 2021-12-14 2024-08-13 몰리큘라 파트너스 아게 이중 결합 특이성을 갖는 설계된 반복 도메인과 이의 용도
AU2023233838A1 (en) 2022-03-15 2024-09-26 Adrenomed Ag Stable aqueous formulation of an anti-adrenomedullin (adm) antibody or anti-adm antibody fragment
KR20250042158A (ko) 2022-07-29 2025-03-26 아드레노메드 아게 쇼크의 요법 또는 예방에 사용하기 위한 항-아드레노메둘린 (ADM) 항체 또는 항-ADM 항체 단편 또는 항-ADM 비-Ig 스캐폴드
WO2024023368A1 (en) 2022-07-29 2024-02-01 4TEEN4 Pharmaceuticals GmbH Prediction of an increase of dpp3 in a patient with septic shock
EP4565606A1 (en) 2022-08-01 2025-06-11 Molecular Partners AG Charge modified designed repeat domains and their use
WO2024038307A1 (en) 2022-08-19 2024-02-22 Novartis Ag Dosing regimens for sars-cov-2 binding molecules
WO2024059686A2 (en) * 2022-09-15 2024-03-21 The Regents Of The University Of California Darpin backbones and rigidified electron microscopy imaging scaffolds
WO2024126793A1 (en) 2022-12-15 2024-06-20 4TEEN4 Pharmaceuticals GmbH Dpp3 inhibitor for improvement of pulmonary function in critically ill patients
EP4673159A1 (en) 2023-02-27 2026-01-07 Molecular Partners AG Darpins for use in reducing renal accumulation of drugs
CN120731367A (zh) 2023-03-17 2025-09-30 Pam治疗诊断有限公司 肽基甘氨酸α-酰胺化单加氧酶(PAM)的测定方法及其诊断用途
CN120857945A (zh) 2023-03-29 2025-10-28 4Teen4制药有限公司 用于在血压下降的危重病患者中保护心肌和预防心肌损伤的dpp3抑制剂
WO2025068313A1 (en) 2023-09-25 2025-04-03 Sphingotec Gmbh A method for early diagnosis, early prediction, monitoring or prediction of severity of reduced graft function in a kidney transplantation patient
WO2025146491A1 (en) 2024-01-05 2025-07-10 Molecular Partners Ag Designed repeat domains with dual binding specificity for cd117 and cd47-binding agent
WO2025229075A1 (en) 2024-05-03 2025-11-06 Sphingotec Gmbh A method for the specific determination of proenkephalin fragment 119-159
WO2025248139A1 (en) 2024-05-31 2025-12-04 4TEEN4 Pharmaceuticals GmbH Use of adrenomedullin or fragments thereof in the treatment of a patient in need thereof
EP4675277A1 (en) 2024-07-05 2026-01-07 Predemtec AG A method for diagnosing alzheimer´s disease or determining the risk of suffering from alzheimer´s disease

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4308689A (en) 1988-09-02 1990-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5348867A (en) 1991-11-15 1994-09-20 George Georgiou Expression of proteins on bacterial surface
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
CA2196496A1 (en) 1997-01-31 1998-07-31 Stephen William Watson Michnick Protein fragment complementation assay for the detection of protein-protein interactions
CN100480269C (zh) 1997-04-07 2009-04-22 基因技术股份有限公司 抗-血管内皮生长因子的抗体
PT1787999E (pt) 1997-04-07 2010-11-11 Genentech Inc Anticorpos anti-vegf
DE69834032T2 (de) 1997-04-23 2006-12-07 Universität Zürich Verfahren zur erkennung von nucleinsäuremolekülen codierend für (poly)peptide, welche mit zielmolekülen interagieren
US6416950B1 (en) 1998-12-02 2002-07-09 Phylos, Inc. DNA-protein fusions and uses thereof
CA2376379C (en) 1999-06-08 2007-08-07 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US7087411B2 (en) * 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
EP1332209B1 (en) * 2000-09-08 2009-11-11 Universität Zürich Collections of repeat proteins comprising repeat modules
RU2299208C2 (ru) * 2001-05-08 2007-05-20 Шеринг Акциенгезельшафт Антраниламидпиридинамиды избирательного действия в качестве ингибиторов vegfr-2 и vegfr-3
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
US7772188B2 (en) * 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
AU2004296376B2 (en) * 2003-12-05 2010-03-04 Bristol-Myers Squibb Company Inhibitors of type 2 vascular endothelial growth factor receptors
EP1812026A2 (en) * 2004-11-12 2007-08-01 Schering Aktiengesellschaft Recombinant newcastle disease virus
LT2586459T (lt) * 2005-03-25 2017-09-25 Regeneron Pharmaceuticals, Inc. Vegf antagonisto kompozicijos
EP1902131B1 (en) 2005-07-08 2009-11-11 University of Zurich Phage display using cotranslational translocation of fusion polypeptides
AU2007325838B2 (en) * 2006-11-22 2013-09-19 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR
ZA200904860B (en) * 2007-02-01 2010-09-29 Genentech Inc Combination therapy with angiogenesis inhibitors
ATE516814T1 (de) 2007-02-02 2011-08-15 Bristol Myers Squibb Co 10fn3 domain zur behandlung von krankheiten begleitet von unerwünschter angiogenese

Similar Documents

Publication Publication Date Title
JP2012507271A5 (Direct)
RU2011122201A (ru) Связывающие белки, ингибирующие взаимодействия vegf-a рецептора
JP2015522576A5 (Direct)
JP2010529860A5 (Direct)
JP2013534812A5 (Direct)
JP2012518420A5 (Direct)
RU2017134456A (ru) Рекомбинантные связывающие белки и их применение
JP2014501510A5 (Direct)
JP2012525844A5 (Direct)
RU2014150224A (ru) Сконструированный белок с анкириновым повтором, связывающийся с фактором роста тромбоцитов
JP2006506942A5 (Direct)
JP2011502479A5 (Direct)
JP2009511579A5 (Direct)
JP2012531889A5 (Direct)
JP2019506841A5 (Direct)
JP2010519252A5 (Direct)
JP2010519931A5 (Direct)
RU2010122053A (ru) Иммуносупрессорные полипептиды и нуклеиновые кислоты
JP2018522563A5 (Direct)
JP2012082206A5 (Direct)
PE20221909A1 (es) Moleculas de union a antigeno que comprenden un trimero de ligando de la familia de tnf
JP2010273685A5 (Direct)
JP2020503262A5 (ja) アクチビンIIa型受容体変異体および同変異体を含む医薬組成物
JP2014520120A5 (Direct)
IL278418B2 (en) Vaccine composition